Activity provided by the American Epilepsy Society
Recording date: April 3, 2020
Activity Launch date: April 10, 2020
Expiration date: April 10, 2023
Please review all activity information below. To receive credit for this activity you must view the presentation and complete the evaluation.
Note: A downloadable PDF of the slide set is available under the "Resources Tab" of the presentation.
This enduring activity is a free resource to members and non-members.
The need for telehealth is here and the urgency and intricacy of implementing it can be overwhelming. This webinar provides an introduction to telehealth from providers with extensive experience using telehealth successfully in their own epilepsy practices. We discuss ways to provide telehealth services for epilepsy care, the unique aspects of working with epilepsy patients in this way, and how to bill for these services.
Epileptologists, neurologists, advanced practice providers, nurses, allied health professionals, clinical trainee students, and fellows
Following participation in this activity the learner should be able to:
- List methods to provide telehealth services for epilepsy care
- Explain the unique aspects of providing epilepsy care via telehealth
- Describe how to bill for telehealth epilepsy services
It is the policy of the American Epilepsy Society (AES) to ensure balance, independence, objectivity and scientific rigor. All individuals involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. Conflicts of interest will be resolved by AES prior to an educational activity being delivered to learners.
Planning Committee, Faculty, Reviewers' Disclosures of Financial Relationships
In accordance with the ACCME Standards for Commercial Support, the AES requires that any person who is in a position to control content of a CME activity must disclose all relevant financial relationships that they have with a commercial interest. The following individuals contributed to this activity’s content.
Barbara C. Jobst, MD, Dartmouth Hitchcock Medical Center,
Dr. Jobst has disclosed the following relevant relationships:
Research support from the following entities: Neuropace; Medtronic; Eisai; Harvard Pilgrim; NIH; CDC; NSF; DARPA; and Editor of Neurology and Epilepsia
Fred A. Lado, MD, PhD, Northwell Health, Great Neck, NY
Dr. Lado had indicated he has no financial relationships to disclose relevant to this activity
Madona Plueger, ACNS, CNRN, MSN, Barrow Neurological Institute, Phoenix, AZ
Dr. Plueger has indicated that she has no financial relationships with commercial interests to disclose
Jeannine Conway, PharmD, BCPS, Moderator, University of Minnesota College of Pharmacy, Minneapolis, MN
Dr. Conway has disclosed the following relevant relationships:
- UCB Pharma Inc.: Epilepsy Pharmacist Working Group; consulting fee
- Greenwich Biosciences: Cannabinoid Education Working Group; honoraria
David M. Ficker, MD, Chair, AES Webinar Workgroup, Cincinnati Medical Center, Cincinnati, OH
Dr. Ficker has disclosed the following relevant relationships:
Greenwich Biosciences (speaker); and Best Doctors Inc. (consultant)
Marvin A. Rossi, MD, PhD, Rush University Medical Center, Chicago, IL
Dr. Rossi has disclosed the following relevant relationships:
CDBG; Foglia Family Foundation; Adelaide Cervantes Epilepsy Fund; and UCB
Edward “Rusty" J. Novotny, Jr., MD, University of Washington School of Medicine, Seattle, WA
Dr. Novotny has indicated he has no financial relationships to disclose relevant to this activity
Carl W. Bazil, MD, PhD, Columbia University, New York, NY
Dr. Bazil has disclosed the following relevant relationships:
Editorial Boards: JAMA Neurology, Current Neurology, Neuroscience Reports, and the Medical Letter; and PI (study) for UCB Pharma (no salary support)
Jay Salpekar, MD, Kennedy Krieger Institute,Baltimore, MD
Dr. Salpekar has disclosed the following relevant relationships:
Lundbeck: Investigator initiated study- research funding to institution only; contracted research
Elaine Sing-Wah Seto, MD, PhD
Dr. Seto has indicated she has no financial relationships with commercial interests to disclose
American Epilepsy Society Staff Planners
Amy Kephart, MPH, American Epilepsy Society, Chicago, IL
Ms. Kephart has indicated she has no financial relationships to disclose relevant to this activity
Cristina Graham, American Epilepsy Society, Chicago, IL
Ms. Graham has indicated she has no financial relationships to disclose relevant to this activity
Resolution of Conflicts of Interest
It is the policy of the American Epilepsy Society to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. In accordance with the ACCME Standards for Commercial Support of CME, the AES implemented the mechanisms of prospective peer review of this CME activity, to identify and resolve any conflicts. Additionally, the content of this activity is based on the best available evidence.
The American Epilepsy Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
For more information regarding contact hours, please call American Epilepsy Society 312.883.3800.
The American Epilepsy Society designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This activity is planned and implemented by the University of Minnesota, Interprofessional Continuing Education and American Epilepsy Society. In support of improving patient care, University of Minnesota, Interprofessional Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The Universal Activity Number (UAN) for this webinar is:
This knowledge-based online activity has been approved for 1.0 contact hours.
International Credits: The American Medical Association has determined that non-US. licensed physicians who participate in this CME activity are eligible for AMA PRA Category 1 Credits™.
Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program.
CME and CE Certificates
To receive credit for your participation in this activity, please complete the evaluation survey provided at the conclusion of the activity.
Unapproved Use Disclosure
The American Epilepsy Society requires CME authors to disclose to learners when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Information about pharmaceutical agents/devices that is outside of U.S. Food and Drug Administration approved labeling may be contained in this activity.
This CME activity is for educational purposes only and does not constitute the opinion or endorsement of, or promotion by, the American Epilepsy Society. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label, investigational and/or experimental uses.